Key stats
About AdvisorShares Psychedelics ETF
Home page
Inception date
Sep 15, 2021
Structure
Open-Ended Fund
Replication method
Synthetic
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
AdvisorShares Investments LLC
Distributor
Foreside Fund Services LLC
PSIL is an actively-managed portfolio of publicly-listed companies that derive at least 50% of their revenue or devote 50% of their assets to legal activities related to psychedelic medicines and their derivatives, excluding cannabis. It invests in stocks of US and foreign mid-, small-, and micro-cap firms and in swaps that provide the same exposure. PSIL aims to concentrate at least 25% of its investments in the Pharmaceuticals, Biotechnology & Life Sciences industry group. The fund adviser uses outside analyst ratings and stock selection rating tools to select companies that dominate their respective industries or are in unique positions for growth and expansion. Additionally, the fund has the ability to engage in stock lending, up to 33.3% of the portfolio, in order to increase income to the issuer.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.83%
Health Technology97.20%
Non-Energy Minerals1.86%
Health Services0.77%
Bonds, Cash & Other0.17%
Mutual fund0.17%
Cash0.00%
Stock breakdown by region
North America71.55%
Europe27.86%
Oceania0.59%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
PSIL invests in stocks. The fund's major sectors are Health Technology, with 97.20% stocks, and Non-Energy Minerals, with 1.86% of the basket. The assets are mostly located in the North America region.
PSIL top holdings are ATAI Life Sciences N.V. and Quantum Biopharma Ltd. Subordinate Voting Shares Class B, occupying 9.53% and 8.85% of the portfolio correspondingly.
PSIL last dividends amounted to 0.16 USD. The quarter before, the issuer paid 0.05 USD in dividends, which shows a 66.49% increase.
PSIL assets under management is 10.38 M USD. It's risen 22.25% over the last month.
PSIL fund flows account for 1.85 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, PSIL pays dividends to its holders with the dividend yield of 2.32%. The last dividend (Mar 28, 2025) amounted to 0.16 USD. The dividends are paid quarterly.
PSIL shares are issued by Wilson Lane Group LLC under the brand AdvisorShares. The ETF was launched on Sep 15, 2021, and its management style is Active.
PSIL expense ratio is 0.99% meaning you'd have to pay 0.99% of your investment to help manage the fund.
PSIL follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
PSIL invests in stocks.
PSIL price has risen by 21.76% over the last month, and its yearly performance shows a 25.13% increase. See more dynamics on PSIL price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 17.60% over the last month, showed a 13.08% increase in three-month performance and has increased by 25.77% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 17.60% over the last month, showed a 13.08% increase in three-month performance and has increased by 25.77% in a year.
PSIL trades at a premium (1.57%) meaning the ETF is trading at a higher price than the calculated NAV.